PRECISION OPTICS CORPORATION, INC. (POCI) stock intrinsic value fair value estimate & owner earnings analysis

Precision Optics, based in Gardner, Massachusetts, designs and manufactures very small optical instruments: micro-endoscopes and optical assemblies built to order for medical device companies, custom lenses and assemblies sold through its Ross Optical unit in El Paso, Texas, and micro-optics for defence and aerospace programmes. In fiscal 2026 (year to June 30, 2026) revenue jumped 65% to $31.5 million, almost entirely because a single-use cystoscope programme it had designed for a customer moved into production; systems manufacturing rose from 43% to 72% of sales. The other side of that change is concentration: one customer was 41% of revenue and another 27%, and the filings disclose no long-term supply contract or backlog behind those orders. The record. We measure what the business leaves for its owners after working-capital swings, the cost of stock issued to employees, and the capital spending needed to keep it running. On that measure Precision Optics has not had a single positive year in the last ten. The shortfall was $0.6 to $1.5 million a year from fiscal 2017 to 2023, widened to $3.0 million in fiscal 2024 and $5.7 million in fiscal 2025, and narrowed to $3.4 million in fiscal 2026. Stock compensation is a large part of the cost, $1.1 to $1.6 million a year on a business with gross profit of $3 to $5 million. The losses have been paid for by selling shares: the share count roughly tripled over the decade on a split-adjusted basis, and the company sold 3.19 million shares at $3.60 in March 2026, raising $10.6 million. Fiscal 2026 also included a one-time benefit of about $0.3 million from tariff refunds. Our earlier figures for this company were built without the working-capital adjustment and are not comparable to these. What changed in the business. The cystoscope ramp did move the company toward breakeven: the operating loss was about $64,000 in the March 2026 quarter and about $107,000 in the June quarter, against $2.0 million in the March 2025 quarter, and gross margin in those two quarters was 24 to 25% compared with 17% for the full year. Two quarters is real evidence that the higher volume can cover the overhead, but it rests on one customer's orders, and the engineering pipeline that feeds future production fell 30% because, in the company's words, there were insufficient new product development engagements. Balance sheet. At June 30, 2026 the company held $9.8 million of cash against $1.3 million of bank debt. The lender waived a missed debt-service covenant for the third year running in September 2026 and replaced it with a requirement to keep at least $2.0 million of liquidity, so we treat $2.0 million as cash the business must hold and $7.8 million as surplus. Net of debt, that surplus is worth about $6.5 million, or roughly $0.59 a share on 10.97 million shares. Most of what the shares are worth in every case is this cash, less whatever the business consumes. Base case: the cystoscope programme continues at roughly current volumes but the overhead, stock compensation and capital needs of the business are not fully covered, so the business consumes about $0.65 million a year, halfway between its ten-year record and the last two quarters. We credit no growth: there is no contract, backlog or long record of repeatable expansion to put it in the bag, and nothing in the filings evidences earning power beyond the ten-year horizon, so the story ends there. The business itself is worth about negative $4.8 million; add $6.5 million of surplus cash net of debt and the shares are worth about $1.7 million, or $0.16 a share. Bear case: the 41% customer slows, re-sources or ends the programme, which the filings flag as a material risk with no contractual protection, and the company returns to the losses of fiscal 2024 to 2025, burning $3 to $4 million a year. That is not an imagined disaster; it is the company's own result from two years ago. On that path the business consumes about $9.8 million over three years, more than its surplus cash, the bank's $2.0 million liquidity floor is breached, and it would have to sell shares again at whatever price it could get. The company would then owe and consume more than it is worth by about $3.2 million, roughly negative $0.30 a share, which in practice shows up as heavy dilution of today's holders. Bull case: the two recent quarters prove representative, the cystoscope programme holds, and Ross Optical and the micro-optics lab recover modestly, so the business produces about $1 million a year for owners for ten years before fading as nothing evidenced carries it further. The business is worth about $7.4 million, plus $6.5 million of net surplus cash, about $13.9 million or $1.27 a share. We did not include new design wins converting into production, the recovery of defence orders delayed at the micro-optics lab, or margin expansion, because none is yet secured. Margin-of-safety price. We are not confident of the earnings level: the company has never produced positive owner earnings in ten years, and the recent improvement rests on one customer's product, one year old in production, with no disclosed contract. The worst plausible outcome is losing that customer, and the structure would not absorb it comfortably: cash covers about two to three years of the old loss rate, the bank has already had to waive covenants three times, and the only source of more money has been new shares. If we are wrong about the durability of the cystoscope orders, the shares are worth less than nothing to today's holders; if we are wrong about how much overhead the new volume really covers, they are worth little more than the cash. The business pays nothing while waiting. At today's results there is no price at which we can be confident of a 20% annual return, because the value of the shares depends on whether the losses have actually stopped. If the company proves they have, by producing two consecutive full years of positive owner earnings without selling shares to fund operations, the business would be earning roughly $1 million a year on about 11 million shares with its cash intact, worth around $1.20 to $1.30 a share; $0.70 would be little more than the cash for a business that had finally shown it could stand on its own, leaving enough room to reach a 20% return even if earnings then slipped back toward breakeven. That is the margin-of-safety price, effective once that condition is met.